

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and *BRCA1* loss

Blaise Clarke^{1,5}, Anna V Tinker^{2,5}, Cheng-Han Lee¹, Subbaya Subramanian³, Matt van de Rijn³, Dmitry Turbin¹, Steve Kalloger¹, Guangming Han¹, Kathy Ceballos¹, Mark G Cadungog⁴, David G Huntsman¹, George Coukos⁴ and C Blake Gilks¹

¹Genetic Pathology Evaluation Center of the Prostate Research Center, Department of Pathology, Vancouver General Hospital and British Columbia Cancer Agency, Vancouver, BC, Canada; ²Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada; ³Department of Pathology, Stanford University Medical Center, Stanford, CA, USA and ⁴Center for Research on Ovarian Cancer Early Detection and Cure, University of Pennsylvania, Philadelphia, PA, USA

Intraepithelial tumor-infiltrating T cells have been correlated with improved outcomes in ovarian carcinoma, however, it is not known whether there is an association with disease stage, histological subtype, or *BRCA* mutation/expression. Two case series of ovarian carcinomas were included in the study; a retrospective series of 500 patients, and 40 prospectively collected cases fully characterized for *BRCA1* mutation status and expression. Intraepithelial immune cells were assessed as present or absent by immunohistochemical staining of tissue microarrays. In the retrospective case series, the presence of intraepithelial CD8⁺ T-cells correlated with improved disease-specific survival ($P=0.027$), whereas intraepithelial CD3⁺ T cells did not ($P=0.49$). For serous ovarian carcinomas, the presence of intraepithelial CD3⁺ and CD8⁺ T-cells correlated with improved disease-specific survival ($P=0.0016$ and $P\leq 0.0001$, respectively). The presence of intraepithelial CD8⁺ T cells was not associated with improved survival in endometrioid or clear cell carcinomas. On multivariate analysis, disease stage and CD8⁺ T cells were found to be independently predictive of improved disease-specific survival, whereas grade, age at surgery, and type of adjuvant treatment were not. In the prospective patient cohort, intraepithelial CD8⁺ T-cells correlated with the presence of mutation or loss of expression of *BRCA1* through promoter methylation ($P=0.019$). Intraepithelial CD8⁺ tumor-infiltrating T-cells correlate with improved clinical outcomes for all stages of ovarian cancer; this association is restricted to the serous ovarian cancer subtype, and is an independent prognostic factor on multivariate analysis. The presence of intraepithelial CD8⁺ T cells also significantly correlates with loss of *BRCA1*.

Modern Pathology advance online publication, 5 December 2008; doi:10.1038/modpathol.2008.191

Keywords: T cells; ovarian carcinoma; BRCA; prognosis; serous carcinoma; tumor-infiltrating lymphocytes

Ovarian cancer is the leading cause of mortality among gynecologic malignancies and the fifth leading cause of cancer death in women.¹ Clinical prognostic factors include factors reflecting intrinsic tumor biology (stage and grade), patient factors (eg age, fitness to tolerate treatment), treatment factors (eg extent of surgical debulking), and the response to first line treatment.² Despite high initial response

rates to chemotherapy and the demonstrated improvements in median overall survival, fewer than 40% of patients with advanced disease survive to 5 years.³

Many potential molecular prognostic factors in ovarian cancer have been investigated (eg *HER2*, *TP53*).⁴ Most factors were identified in small studies and have not been reproduced or independently validated, precluding clinical utility. In addition, mutations of the *BRCA1* and 2 tumor suppressor genes have been associated with improved clinical outcomes^{5–7} but the biologic mechanisms underlying these findings are not well understood to date.

The prognostic significance of the host immune response, as defined by the presence of tumor-infiltrating lymphocytes, has been studied in ovarian

Correspondence: Professor CB Gilks, MD, Genetic Pathology Evaluation Center of the Prostate Research Center, Department of Pathology, Vancouver General Hospital and British Columbia Cancer Agency, Room 1259, 1st Floor JPPN, 855 West 12th Avenue, Vancouver, BC, V5Z 1M9 Canada.
E-mail: Blake.Gilks@vch.ca

⁵These authors contributed equally to this work.
Received 30 June 2008; revised 13 October 2008; accepted 19 October 2008; published online 5 December 2008

cancer^{8–11} and other cancers^{12–18} Zhang *et al*¹⁰ identified intratumoral (later named intraepithelial) CD3⁺ T-cell infiltration to be an independent prognostic factor in 186 advanced ovarian cancers. Curiel *et al*⁸ demonstrated that infiltration of CD4⁺ CD25⁺ regulatory T-cells carried a worse prognosis in ovarian cancer. More recently, immunohistochemical evaluation of intraepithelial tumor-infiltrating lymphocytes in two cohorts of epithelial ovarian cancer of all cell types and stages showed that cases having a higher frequency of intraepithelial CD8⁺ tumor-infiltrating lymphocytes rather than CD3⁺ cells had improved survival compared to patients with lower frequencies.^{9,11} Therefore, the immune response to ovarian cancer may serve as a novel prognostic marker. However, it remains unknown whether tumor histotype, stage or molecular pathogenesis affect the presence or the predictive value of intraepithelial tumor-infiltrating lymphocytes.

We used a large, population-based, clinically annotated, retrospective cohort of ovarian carcinomas treated according to standardized protocols from the province of British Columbia to assess for immune cell infiltrates using immunohistochemistry on tissue microarrays. The results were correlated with patient outcomes. In addition, we used an unselected, consecutive series of nonmucinous epithelial ovarian carcinomas that were extensively characterized for *BRCA1* and *BRCA2* mutation and expression status to determine whether T-cell infiltration is associated with *BRCA* status.¹⁹

Materials and methods

Patients

Most women diagnosed with ovarian cancer in British Columbia are referred to a British Columbia Cancer Agency-affiliated cancer treatment center, and provincial therapy guidelines are widely followed. We included all 832 epithelial ovarian cancer cases seen in the province of British Columbia from 1984 to 2000 that were stage I, grades 2 and 3, or stages II–III, any grade, and surgically cytoreduced to microscopic residual. All cases with residual macroscopic disease following surgery were excluded from this analysis. Histopathological features of this case series have been described in detail previously.²⁰ Blocks for tissue microarray construction were available for 500 cases and these cases constitute the retrospective case series. Tumor grade was assigned according to the Silverberg grading system,²¹ but all clear cell carcinomas were considered to be high grade (grade 3). All mucinous carcinomas were of intestinal type; there were no mucinous carcinomas of endocervical type.

A second cohort consisted of 49 consecutive patients with stages I–III nonmucinous epithelial ovarian carcinoma recruited into a prospective study examining *BRCA1* expression and mutation

status at Vancouver General Hospital, as recently reported.¹⁹ A third cohort consisted of 29 cases of ovarian surface epithelial carcinoma where the number of intraepithelial CD8⁺ tumor-infiltrating lymphocytes was compared in whole sections vs tissue microarrays, constructed as described below. Approval for the study was obtained from the research ethics committee of the University of British Columbia.

Tissue Microarrays

Following pathology review, a representative area of each tumor was selected and duplicate 0.6 mm core tissue microarrays were constructed, as described previously.²²

Immune Marker Analysis

Tissue microarrays were subjected to immunohistochemical analysis using antibodies against human CD3 (polyclonal, 1:300; Cell Marque), CD4 (clone 4B12, 1:50; Novocastra), CD8 (clone C8/144B, 1:50; Dako), CD20 (clone L26, 1:250; Dako), CD43 (clone MT1, 1:100; Vector), CD117 (polyclonal, 1:200; Dako), and granzyme-B (clone GrB-7, 1:25; Dako). Each 0.6 mm core was examined at $\times 20$ magnification and scored simultaneously by two pathologists, who reached a score by consensus. Intraepithelial cells were defined strictly as being those within the epithelial component of the tumor (tumor islets), and were reported as being either present (ie one or more intraepithelial lymphocytes present in the two 0.6 mm cores for a given case) or absent. In the case of mast cells (CD117), the presence of any mast cells, whether stromal or epithelial, was recorded as a positive result. Data on immunostaining are not available for all 500 cases for all markers, primarily because of cores not containing tumor or not adhering to slides during processing. A second tissue microarray comprising the prospective case series was stained for CD8 exactly as above.

Unstained sections from the 500-case retrospective series described above were also transferred to a second laboratory, where they were interpreted independently, as described previously.¹⁰ Briefly, tissue sections were stained using polyclonal rabbit antihuman CD3 (Dako) and intraepithelial CD3⁺ tumor-infiltrating lymphocytes were classified as either present or absent.

In a cohort of 29 cases, whole sections were stained for CD8 and intraepithelial CD8⁺ cells were counted in 10 consecutive high power fields. This was carried out in five sets of 10 high power fields (total of 50 high power fields), and the results expressed as the average count per 10 high power fields for these five sets, to allow comparison with the results of assessment of intraepithelial CD8⁺ T cells in tissue microarray cores from the same blocks.

BRCA Analyses

The prospective cohort cases were previously characterized for *BRCA1* and *BRCA2* mutation status (germline and somatic), *BRCA1* promoter hypermethylation, and *BRCA1* mRNA and protein expression, as described elsewhere.¹⁹ Results for all assays were available for 47 cases and based on these results the tumors were divided into five groups: (1) tumors with a *BRCA1* mutation ($n=9$); (2) tumors with epigenetic loss of *BRCA1* expression (no *BRCA1* or *BRCA2* mutation, methylation of the *BRCA1* promoter, absence of immunostaining for *BRCA1* in the tumor cells, and decreased *BRCA1* mRNA expression; $n=9$); (3) tumors with no abnormalities of *BRCA1* or *BRCA2* ($n=22$); (4) tumors equivocal for *BRCA1* epigenetic loss (no mutations or methylation of the *BRCA1* promoter, but decreased *BRCA1* mRNA, protein, or both; $n=4$); and (5) tumors with a *BRCA2* mutation ($n=3$). The cases with *BRCA2* mutation or equivocal for *BRCA1* loss ($n=7$) were excluded from further analysis as there were too few cases in these two groups, leaving a cohort of 40 cases for analysis of intratumoral T-cell infiltrates.

Gene Expression Analysis

In 34 cases of high-grade serous carcinoma from the Vancouver General Hospital prospective case series of 49 cases, tumor tissue was snap frozen at the time of primary surgery and gene expression profiling was performed. Only high-grade serous carcinomas were studied by gene expression profiling based on data presented herein showing that intraepithelial tumor-infiltrating lymphocytes are of prognostic significance primarily in this subtype of ovarian cancer. The Human Exonic Evidence-Based Oligonucleotide (HEEBO; Stanford) microarrays used in the study contained 44 544 70mer probes that were designed using a transcriptome-based annotation of exonic structure for genomic loci (<http://www.microarray.org/sfgf/>). After confirmation of the presence of viable tumor by frozen section, the tissue fragment was homogenized in Trizol reagent (Invitrogen, Carlsbad, CA, USA) and total RNA was extracted. Microarray hybridization and washing was performed using standard procedures.^{23,24} Only spots with a ratio of signal over background of at least 1.3 in the Cy5 and 1.5 in the Cy5 channel were included. For data analysis, a set of standard filtering criteria was employed using only genes with 80% available good data that showed a minimum of fourfold variation from the mean expression level across all samples in at least three samples.

Statistical and Biocomputational Analyses

Statistical analyses of immune markers were performed with JMP v6.0.3 (SAS Institute, Carey, NC,

USA) software. Univariable survival analysis was computed using the Kaplan–Meier method and statistical differences were determined using the log-rank test. Multivariable disease-specific survival analysis was carried out using the proportional hazards model. Immunohistochemical marker associations with histopathologic subtype and *BRCA* status were compared with the Pearson χ^2 -statistic. Multivariate correlations between various immunohistochemical markers were computed with the Kendall τ_b -statistic. P -values <0.05 were regarded as significant for all analyses. For comparison of interlaboratory assessment of intraepithelial T cells, κ -statistics were calculated.

For the gene expression study, unsupervised hierarchical clustering analysis was used to produce dendrograms that depict the degree of relatedness between tumor specimens based on their gene expression profiles.²⁵ Significance analysis of microarrays²⁶ was performed to identify differentially expressed genes between groups of tumor specimens. A false discovery rate of less than 0.05 was considered significant. Gene Ontology Term Finder analysis was performed using the online program from Stanford Microarray Database (<http://smd.stanford.edu/cgi-bin/ontology/showTermFinder.pl>) to identify enrichment of genes related to specific biological processes in each gene subcluster and a corrected P -value of <0.05 was considered significant.

Results

Patient Characteristics for the Retrospective Case Series

The median age at diagnosis was 58.1 years (range: 25.4–89.0 years). Patient characteristics are summarized in Supplementary Table 1. Of the 500 patients, 205 (41.0%) had stage I disease, 211 (42.2%) had stage II disease, and 84 (16.8%) had stage III disease. Of the four major tumor cell types, 212 cases were serous, 132 clear cell, 125 endometrioid, and 31 were mucinous carcinoma. When the cohort was divided into early (stages I and II) and late stage (stage III) cases, there were 143 serous cancers, 124 clear cell carcinomas, 119 endometrioid carcinomas, and 30 mucinous carcinomas in the early stage group, and 69 serous carcinomas, 8 clear cell, 6 endometrioid, and 1 mucinous in the advanced stage group. The median duration of follow-up was 5.3 years (range 0.1–18.0 years).

Prevalence of Immune Cell Infiltrates

Intraepithelial T cells

Intraepithelial CD3⁺, CD8⁺, and CD4⁺ T cells were detected in 60.4, 57.0, and 26.6% of cases, respectively (Supplementary Table 2). The frequency of CD8⁺ T-cell infiltration according to stage, grade,

and histology is summarized in Table 1. Of note, CD8+ T cells were more commonly present in serous carcinomas, compared to either endometrioid or clear cell carcinomas ($P=0.0016$ and $P<0.001$, respectively).

Other intraepithelial immune/inflammatory cells

The frequency of the presence of other immune cells in the retrospective case series is shown in Supplementary Table 2. Correlations between the presence of the different immune cells within these cases are presented in Table 2, with the Kendall τ -statistic presented for each pairwise comparison; significant correlations are indicated in bold ($P<0.05$). This analysis shows that there are significant positive correlations between expression of all markers of immune cell infiltrates in ovarian carcinoma stu-

died, with the exception of mast cells (CD117); the presence of CD117+ mast cells does not significantly correlate with the presence of any of the other cells.

Intraepithelial T Cells and Correlation with Patient Outcome

The presence of intraepithelial CD8+ tumor-infiltrating lymphocytes correlated with clinical outcomes when the cohort of 500 cases was analyzed. None of the other markers correlated with survival in the entire retrospective dataset. Intraepithelial CD8+ tumor-infiltrating lymphocytes correlated with improved disease-specific survival (disease-specific survival; $P=0.027$; Figure 1a) but not with progression-free survival ($P=0.13$) or overall survival ($P=0.34$) in the entire cohort.

Univariate analysis according to stage and cell type demonstrated that the presence of intraepithelial CD8+ tumor-infiltrating lymphocytes was significantly correlated with improved disease-specific survival ($P=0.012$), PFS ($P=0.027$) and OS ($P=0.010$) for stage III cancers, most of which (69/84, 82%) were of serous type (Figure 1b). Presence of intraepithelial CD8+ tumor-infiltrating lymphocytes approached significance as a correlate of disease-specific survival in early stage (stages I and II) cancers ($P=0.052$; Figure 1c). Analysis based on primary cell type showed that CD8+ tumor-infiltrating lymphocytes correlated with improved disease-specific survival in serous ($P=0.0001$; Figure 1d) and mucinous ($P=0.01$, data not shown) cancers, but not in endometrioid ($P=0.79$) or clear cell ($P=0.6$) cancers.

The presence of intraepithelial CD3+ tumor-infiltrating lymphocytes did not correlate with outcome when the entire cohort was examined by Kaplan–Meier survival analyses ($P=0.49$; Figure 2a). However, intraepithelial CD3+ tumor-infiltrating lymphocytes correlated with improved progression-free survival ($P=0.01$) and disease-specific survival ($P=0.0087$) in the subset of advanced stage (stage III) ovarian cancers (Figure 2b); as noted previously, the stage III cancers in this series consisted of a disproportionately high number of serous carcinomas. Intraepithelial CD3+ TILs were also significantly correlated with improved disease-specific survival in serous carcinomas of any stage ($P=0.005$, data not shown). A significant relationship between the presence of intraepithelial CD3+ TILs and disease-specific survival was not observed with the other histological cell types (clear cell ($P=0.32$); endometrioid ($P=0.62$); mucinous ($P=0.51$)).

No correlation was identified between clinical outcome and the presence of immune/inflammatory cells identified by CD4, CD20, CD43, CD117, or granzyme-B immunostaining (data not shown).

Table 1 CD8+ intraepithelial T-cell infiltration

	Present (%)
<i>Stage at diagnosis</i>	
I	102 of 201 (50.7)
II	124 of 203 (61.1)
III	51 of 82 (62.2)
<i>Histologic subtype</i>	
Serous	155 of 206 (75.2)
Endometrioid	70 of 121 (57.8)
Clear cell	42 of 129 (32.5)
Mucinous	10 of 30 (33.3)
<i>Grade</i>	
1	50 of 100 (50.0)
2	62 of 108 (57.4)
3	165 of 278 (59.3)

Table 2 Correlations among immune/inflammatory cells

Variable	By variable	Kendall τ	Prob > τ
CD117	CD3	0.0292	0.5234
CD20	CD117	0.0959	0.0350
CD20	CD3	0.3256	<0.0001
CD4	CD117	0.0865	0.0602
CD4	CD20	0.3312	<0.0001
CD4	CD3	0.3419	<0.0001
CD43	CD117	0.0572	0.2100
CD43	CD20	0.1678	0.0002
CD43	CD3	0.1868	<0.0001
CD43	CD4	0.1289	0.0050
CD8	CD117	-0.0034	0.9411
CD8	CD20	0.3958	0.0000
CD8	CD3	0.5876	0.0000
CD8	CD4	0.3190	<0.0001
CD8	CD43	0.2178	<0.0001
Granzyme B	CD117	0.0385	0.4044
Granzyme B	CD20	0.3619	<0.0001
Granzyme B	CD3	0.4009	0.0000
Granzyme B	CD4	0.4163	0.0000
Granzyme B	CD43	0.1347	0.0035
Granzyme B	CD8	0.3958	0.0000

Significant correlations are indicated in bold ($P<0.05$).




Figure 1 Kaplan–Meier analysis of intraepithelial CD8⁺ T cells and disease-specific survival in the entire retrospective study cohort (a); in stage III cases (b); in stages I and II cases (c); and in serous carcinomas (d). For each graph the blue line ('0' in the figure legend) indicates those cases without intraepithelial CD8⁺ T cells and the red line ('1' in the figure legend) indicates those cases with intraepithelial CD8⁺ T cells.




Figure 2 Kaplan–Meier disease-specific survival analysis of intraepithelial CD3⁺ T cells in all cases (a); and in stage III cases (b). For each graph the blue line ('0' in the figure legend) indicates those cases without intraepithelial CD3⁺ T cells and the red line ('1' in the figure legend) indicates those cases with intraepithelial CD3⁺ T cells.

On multivariate analysis, stage ($P<0.0001$), tumor cell type ($P=0.048$), and intraepithelial CD8⁺ TILs ($P=0.0074$) were found to be significantly correlated with disease-specific survival

whereas the remaining variables tested (cell type, grade, age, intraepithelial CD3⁺ tumor-infiltrating lymphocytes, and treatment protocol) were not (Table 3).

Table 3 Prognostic significance of clinical and pathological variables in univariate and multivariate disease-specific survival analysis

Variable	Levels	Univariate			Multivariate		
		HR	CI	P	HR	CI	P
Stage	1	0.55	0.43–0.69	<0.0001	0.64	0.49–0.82	<0.0001
	2	0.79	0.63–0.97		0.83	0.66–1.05	
	3	1	—		1	—	
Tumor cell type	Clear cell	1.05	0.76–1.44	<0.0001	0.78	0.49–1.23	0.0481
	Endometrioid	0.51	0.34–0.75		0.77	0.47–1.22	
	Mucinous	1.04	0.57–1.69		1.17	0.62–2.02	
	Serous	1	—		1	—	
Silverberg grade	1	0.56	0.39–0.77	<0.0002	0.63	0.39–0.97	0.1100
	2	1.24	0.94–1.63		1.22	0.90–1.65	
	3	1	—		1	—	
Age ^a	N/A	N/A	N/A	0.0123	N/A	N/A	0.4514
Treatment	Platinum	1.26	1.08–1.47	0.0037	1.08	0.91–1.29	0.3561
	Platinum and XRT	1	—		1	—	
CD3+IEL	0	1.06	0.90–1.24	0.4943	1.11	0.90–1.36	0.3192
	1	1	—		1	—	
CD8+IEL	0	1.19	1.02–1.39	0.0269	1.33	1.08–1.64	0.0074
	1	1	—		1	—	

IEL, intraepithelial lymphocytes; XRT, radiation therapy.

^aHazard ratios and confidence limits for 'age' are not reported due to it being modeled as a continuous variable.

Independent Assessment of CD3⁺ T Cells

Intraepithelial CD3⁺ TILs were prognostically significant for disease-specific survival in the subset of serous ovarian cancers, in univariate analysis, when staining and interpretation were performed in an independent laboratory ($P=0.046$ for the second laboratory, compared to $P=0.013$ in the original laboratory). The interlaboratory agreement in identification of intraepithelial CD3⁺ tumor-infiltrating lymphocytes was high ($\kappa = 0.71 \pm 0.03$).

Intraepithelial T-Cell Infiltration and BRCA Status in the Prospective Series

A second cohort of patients, identified prospectively, underwent detailed analysis to assess *BRCA1* and *BRCA2* mutation status and *BRCA1* promoter hypermethylation and expression (both RNA and protein). Eighteen cases (all high-grade serous carcinomas) showed either *BRCA1* mutation ($n=9$), or epigenetic loss of *BRCA1* (*BRCA1* promoter hypermethylation with transcriptional silencing; $n=9$). Twenty-two cases, including all of the nonhigh-grade serous carcinomas (five endometrioid carcinomas, four clear cell carcinomas, and two grade 1 serous carcinomas), showed no *BRCA1* or *BRCA2* mutation, unmethylated *BRCA1* promoter and normal *BRCA1* mRNA and protein expression. Seventeen of 18 cases with *BRCA1* mutation or loss of *BRCA1* expression through epigenetic silencing had

intraepithelial CD8⁺ tumor-infiltrating lymphocytes, compared to 11 of 19 cases without *BRCA1* abnormalities ($P=0.019$). Considering only the high-grade serous carcinomas in this series, the association between the presence of CD8⁺ T cells and loss of *BRCA1* was of borderline significance ($P=0.05$, single sided); this analysis should be repeated in a larger, independent case series.

Gene Expression Profile Analysis

Unsupervised hierarchical clustering of 34 high-grade serous ovarian carcinomas from the prospective series separated the tumors into two main groups, designated groups A and B (Figure 3) and the genes were separated into five clusters (designated gene clusters 1–5). Carcinomas in group A showed relatively high level expression of genes in gene clusters 2 and 3. Gene Ontology Term Finder analysis showed that gene cluster 3 showed significant enrichment of genes involved in several biological processes that included immune response, antigen processing and presentation, and T-cell activation (Supplementary Table 3), including genes that were shown previously to be highly expressed in a subset of ovarian carcinomas.²⁷ Comparison between the two groups of ovarian carcinomas identified by gene expression profiling revealed that all group A ovarian carcinomas (10 of 10) contained intraepithelial CD8⁺ tumor-infiltrating




Figure 3 Hierarchical clustering of 34 high-grade serous carcinomas. Unsupervised hierarchical clustering based on 4192 filtered genes separates the carcinomas into two main groups, indicated as groups A and B on the dendrogram. The accompanying heatmap shows the expression profiles across the 4192 filtered genes, which cluster into five main groups (gene clusters 1–5) on hierarchical clustering analysis. The heatmap is a visual representation of the data with the x axis corresponding to the tumor specimens and the y axis corresponding to the genes. The level of gene expression in a tumor specimen for a specific gene relative to the mean expression level for that gene across all samples is shown colorimetrically from bright green (lowest gene expression) to bright red (highest gene expression). Gray color indicates missing data point (spot that did not fulfill the filtering criteria).

Table 4 Immune response genes identified by SAM analysis to be significantly upregulated in CD8 positive tumors

<i>Symbol</i>	<i>Name</i>
APOBEC3G	Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G
B2M	β 2-microglobulin
BST2	Bone marrow stromal cell antigen 2
C3	Complement component 3
C4A	Complement component 4A (Rodgers blood group)
C4B	Complement component 4B (Childo blood group)
CD74	CD74 molecule, major histocompatibility complex, class II invariant chain
CFB	Complement factor B
ISG15	ISG15 ubiquitin-like modifier
IFI6	Interferon, α -inducible protein 6
GBP1	Guanylate-binding protein 1, interferon-inducible, 67 kDa
GBP2	Guanylate-binding protein 2, interferon-inducible
GBP3	Guanylate-binding protein 3
HLA-A	Major histocompatibility complex, class I, A
HLA-DMA	Major histocompatibility complex, class II, DM- α
HLA-DMB	Major histocompatibility complex, class II, DM- β
HLA-DPA1	Major histocompatibility complex, class II, DP- α 1
HLA-DPB1	Major histocompatibility complex, class II, DP- β 1
HLA-DQA2	Major histocompatibility complex, class II, DQ- α 2
HLA-DQB2	Major histocompatibility complex, class II, DQ- β 2
HLA-DRA	Major histocompatibility complex, class II, DR- α
HLA-E	Major histocompatibility complex, class I, E
HLA-F	Major histocompatibility complex, class I, F
IFI27	Interferon, α -inducible protein 27
IFI30	Interferon, γ -inducible protein 30
IFI35	Interferon-induced protein 35
IFIH1	Interferon induced with helicase C domain 1
IFIT1	Interferon-induced protein with tetratricopeptide repeats 1
IFIT2	Interferon-induced protein with tetratricopeptide repeats 2
IFIT3	Interferon-induced protein with tetratricopeptide repeats 3
IL15	Interleukin 15
IL32	Interleukin 32
IL6R	Interleukin 6 receptor
OAS1	2',5'-Oligoadenylate synthetase 1, 40/46 kDa
OAS2	2'-5'-Oligoadenylate synthetase 2, 69/71 kDa
OAS3	2'-5'-Oligoadenylate synthetase 3, 100 kDa
PSMB8	Proteasome subunit, β -type, 8
PTPN22	Protein tyrosine phosphatase, nonreceptor type 22 (lymphoid)
RGS1	Regulator of G-protein signaling 1
SECTM1	Secreted and transmembrane 1
TAP1	Transporter 1, ATP-binding cassette, subfamily B (MDR/TAP)
TAP2	Transporter 2, ATP-binding cassette, subfamily B (MDR/TAP)
TNFSF10	Tumor necrosis factor (ligand) superfamily, member 10
VAV1	Vav 1 oncogene

lymphocytes, unlike the carcinomas in group B (17 of 24 contained intraepithelial CD8⁺ tumor-infiltrating lymphocytes), with the difference being statistically significant ($P < 0.05$). Thus, the tumors characterized by higher level expression of a range of immune response related genes are consistently positive for CD8⁺ T cells.

SAM analysis was subsequently performed to identify genes that are differentially expressed between carcinomas that are positive and negative for intraepithelial CD8⁺ tumor-infiltrating lymphocytes. The results of the significance analysis of microarrays are shown in Supplementary Table 4 (false discovery rate < 0.05). Gene Ontology Term Finder analysis of the significantly upregulated genes identified in the CD8⁺ carcinomas by significance analysis of microarrays revealed a significant enrichment of genes involved in immune

response (corrected P -value < 0.05), which are listed in Table 4.

Discussion

Beyond the most basic clinical predictors of outcome (stage, debulking status, etc), ovarian cancers, and in particular high-grade serous ovarian cancers (the most commonly diagnosed histological subtype of ovarian cancer) have not been further subdivisible into prognostic categories. In this study, the use of a large, independent, population-based cohort of ovarian cancer cases debulked to microscopic residual disease provides definitive results on the prognostic significance of immune infiltration in a population of patients with intermediate-risk ovarian cancer, and defines novel associations of T-cell

infiltration with ovarian cancer histologic subtype. Furthermore, we describe for the first time the association between the presence of T-cell infiltration and *BRCA* loss, suggesting a possible link to molecular mechanisms of genetic instability.

Prior work has demonstrated that high-grade serous tumors are frequently associated with *BRCA* mutation or epigenetic loss.¹⁹ We observed a significant association between intraepithelial tumor-infiltrating lymphocytes and *BRCA* mutation or epigenetic loss. Therefore, we have established a novel association between intraepithelial T cells, serous ovarian cancer histology, and *BRCA* mutation status. Similar observations have been made in medullary and atypical medullary breast carcinomas, which are also associated with *BRCA1* mutation and are characterized by a dense lymphocytic infiltrate;^{28,29} these breast cancers are noted for their relatively favorable prognosis despite being high grade, with numerous mitoses. Similarly, colorectal cancers with microsatellite instability are characterized by tumor-infiltrating lymphocytes and also carry a relatively favorable prognosis in spite of being higher grade.³⁰ Whether the presence of immune infiltration is itself the mechanism responsible for the improvement in prognosis or it simply represents an epiphenomenon of other molecular processes linked with better clinical outcomes remains unknown.

We demonstrate that all immune cells covary with one another, possibly clarifying why multiple T-cell markers have been associated with clinical outcomes in ovarian cancer in previous studies.^{16–18} Like Zhang *et al*,¹⁰ we demonstrate (in two separate laboratories using independent testing and analysis) that intraepithelial CD3⁺ tumor-infiltrating lymphocytes correlate with disease-specific survival in serous ovarian carcinomas. Likewise, we have confirmed the results of two recent studies^{9,11} by demonstrating that intraepithelial CD8⁺ tumor-infiltrating lymphocytes correlate with disease-specific survival in the entire study cohort (including all stages and histologies), as well as in the subset of serous ovarian carcinomas. We have demonstrated that the best marker of immune infiltration (from the panel of immune markers chosen for this study) is CD8, as it is the only marker to significantly predict outcome on multivariate analysis.

Our observation that CD8 is superior to CD3 as a marker of immune cell infiltrates highlights the fact that we do not yet know what the best marker of a prognostically significant immune response in ovarian cancer will prove to be. Unsupervised hierarchical clustering analysis separated 34 cases of high-grade serous carcinoma into two groups (A and B), one of which was characterized by expression of a set of genes involved in immune response, antigen processing and presentation, and T-cell activation. It is likely that a marker or combination of markers superior to CD8 will be discovered, particularly when the mechanism underlying the correlation

between immune response and patient outcome is better understood.

In conclusion, we have validated that the presence of intraepithelial CD8⁺ T-cells correlates with improved clinical outcomes in a large cohort of ovarian cancer patients. This association is particularly linked to the serous histology, and this is an important molecular subdivision of this histological subtype. We also observed that intraepithelial tumor-infiltrating lymphocytes were associated with *BRCA* mutation or epigenetic loss, suggesting a possible link to chromosomal instability within tumors. Further studies are needed to understand the underlying molecular pathways responsible for this association between intraepithelial tumor-infiltrating lymphocytes and favorable prognosis.

Acknowledgements

CBG was supported by the National Cancer Institute of Canada (no. 017051) and an unrestricted educational grant from Sanofi-Aventis. GC was supported by NIH P50-CA083638 Ovarian Cancer SPORE. Blaise Clarke was recipient of a fellowship from Eli Lilly. CBG, SK, and DH received support OvCaRe. Patient outcome data and support in data analysis was provided by the Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency.

Disclosure/conflict of interest

The authors have no potential conflicts to report.

References

- 1 Jemal A, Siegel R, Ward E, *et al*. Cancer statistics, 2006. *CA Cancer J Clin* 2006;56:106–130.
- 2 Agarwal R, Kaye SB. Prognostic factors in ovarian cancer: how close are we to a complete picture? *Ann Oncol* 2005;16:4–6.
- 3 Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. *Semin Oncol* 2006;33: S3–S11.
- 4 Crijns AP, Boezen HM, Schouten JP, *et al*. Prognostic factors in ovarian cancer: current evidence and future prospects. The ECCO 12 Educational Book of Eur J Cancer 2003;127–145.
- 5 Ben David Y, Chetrit A, Hirsh-Yechezkel G, *et al*. Effect of *BRCA* mutations on the length of survival in epithelial ovarian tumors. *J Clin Oncol* 2002;20: 463–466.
- 6 Boyd J, Sonoda Y, Federici MG, *et al*. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. *JAMA* 2000;283:2260–2265.
- 7 Chiba T, Ohtani H, Mizoi T, *et al*. Intraepithelial CD8⁺ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. *Br J Cancer* 2004;91:1711–1717.

- 8 Curiel TJ, Coukos G, Zou L, *et al*. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med* 2004;10:942–949.
- 9 Sato E, Olson SH, Ahn J, *et al*. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. *Proc Natl Acad Sci USA* 2005;102:18538–18543.
- 10 Zhang L, Conejo-Garcia JR, Katsaros D, *et al*. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. *N Engl J Med* 2003;348:203–213.
- 11 Hamanishi J, Mandai M, Iwasaki M, *et al*. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. *Proc Natl Acad Sci USA* 2007;104:3360–3365.
- 12 Clemente CG, Mihm Jr MC, Bufalino R, *et al*. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. *Cancer* 1996;77:1303–1310.
- 13 Jass JR. Lymphocytic infiltration and survival in rectal cancer. *J Clin Pathol* 1986;39:585–589.
- 14 Naito Y, Saito K, Shiiba K, *et al*. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. *Cancer Res* 1998;58:3491–3494.
- 15 Nakano O, Sato M, Naito Y, *et al*. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. *Cancer Res* 2001;61:5132–5136.
- 16 Schumacher K, Haensch W, Roefzaad C, *et al*. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. *Cancer Res* 2001;61:3932–3936.
- 17 Fukunaga A, Miyamoto M, Cho Y, *et al*. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. *Pancreas* 2004;28:e26–e31.
- 18 Galon J, Costes A, Sanchez-Cabo F, *et al*. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science* 2006;313:1960–1964.
- 19 Press JZ, De Luca A, Boyd N, *et al*. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. *BMC Cancer* 2008;8:17.
- 20 Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. *Int J Gynecol Pathol* 2000;19:7–15.
- 21 Gilks CB, Ionescu D, Kalloger SE, *et al*. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. *Hum Pathol* 2008;39:1239–1251.
- 22 Makretsov NA, Huntsman DG, Nielsen TO, *et al*. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. *Clin Cancer Res* 2004;10:6143–6151.
- 23 Perou CM, Jeffrey SS, van de Rijn M, *et al*. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. *Proc Natl Acad Sci USA* 1999;96:9212–9217.
- 24 Perou CM, Sorlie T, Eisen MB, *et al*. Molecular portraits of human breast tumours. *Nature* 2000;406:747–752.
- 25 Eisen MB, Spellman PT, Brown PO, *et al*. Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci USA* 1998;95:14863–14868.
- 26 Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci USA* 2001;98:5116–5121.
- 27 Schaner ME, Ross DT, Ciaravino G, *et al*. Gene expression patterns in ovarian carcinomas. *Mol Biol Cell* 2003;14:4376–4386.
- 28 Lakhani SR. The pathology of familial breast cancer: morphological aspects. *Breast Cancer Res* 1999;1:31–35.
- 29 Kuroda H, Tamaru J, Sakamoto G, *et al*. Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. *Virchows Arch* 2005;446:10–14.
- 30 Buckowitz A, Knaebel HP, Benner A, *et al*. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. *Br J Cancer* 2005;92:1746–1753.

Supplementary Information accompanies the paper on Modern Pathology website (<http://www.nature.com/modpathol>)